0257 GMT - Ansell is likely to be the Australian healthcare stock that is most exposed to the impact of U.S. tariffs, Citi analysts write in a note. They acknowledge that breath-tech maker ResMed and medical-tech provider Nanosonics are probably impacted, given their manufacturing footprints, but not to the same extent as Ansell. The personal-protective equipment maker sources a majority of its products from Malaysia and Sri Lanka, both of which are among the countries hardest hit by tariffs, generating more than 40% of its revenue from the U.S. The exclusion of pharmaceuticals from tariffs is a relief for vaccine maker CSL, they add. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 22:57 ET (02:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。